Literature DB >> 7760005

Chemoattractants induce rapid release of the interleukin 1 type II decoy receptor in human polymorphonuclear cells.

F Colotta1, S Orlando, E J Fadlon, S Sozzani, C Matteucci, A Mantovani.   

Abstract

Molecules representative of different classes of chemotactic agents, including formyl-Met-Leu-Phe (FMLP), C5a, leukotriene B4, platelet-activating factor, and interleukin (IL)-8, caused a rapid reduction in the IL-1 binding capacity by human polymorphonuclear leukocytes (PMN), a cell type expressing predominantly the IL-1 type II decoy receptor (IL-1 decoy RII). N-t-Boc-Met-Leu-Phe, an antagonist for the FMLP receptor, inhibited the loss of IL-1 binding capacity induced by FMLP. Monocyte chemotactic protein 1, a chemokine related to IL-8 but inactive on PMN, had no effect on IL-1 binding in this cell type. FMLP was selected for further detailed analysis of chemoattractant-induced loss of IL-1 binding by PMN. The action of FMLP was rapid, reaching 50% of its maximum (80%) at 30 s, the earliest measurable time point, and plateauing between 10 and 30 min. Dose-response analysis revealed that maximal reduction of IL-1 binding was reached at FMLP concentrations that were also optimal for chemotaxis (50% effective dose = 5 x 10(-9) M). The loss of IL-1 binding capacity caused by FMLP was determined by a reduction in receptor number with no change in their affinity. The effect of FMLP on IL-1 receptor (IL-1R) was selective in that the PMN surface structures IL-8R, CD16, CD18, and major histocompatibility complex class I antigens were unaffected under these conditions. Loss of surface IL-1R was not due to an augumented rate of internalization. FMLP caused rapid release of a 45-kD IL-1-binding molecule identified as the IL-1 decoy RII. After FMLP-induced release, PMN reexpressed newly synthesized receptors, reaching basal levels by 4 h. FMLP-induced release of the IL-1 decoy RII did not impair the responsiveness of PMN to IL-1 in terms of promotion of survival and cytokine production. FMLP-induced release of the IL-1 decoy RII was unaffected by protein synthesis inhibitors, was blocked by certain protease inhibitors, and was mimicked by agents (the Ca++ ionophore A23187 and phorbol myristate acetate) that recapitulate elements in the signal transduction pathway of chemoattractant receptors. The time frame and concentration range of chemoattractant-induced rapid release of the IL-1 decoy RII are consistent with the view that IL-1 decoy RII release is an early event in the multistep process of leukocyte recruitment.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760005      PMCID: PMC2192047          DOI: 10.1084/jem.181.6.2181

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  Intravascular IL-8. Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation.

Authors:  D H Hechtman; M I Cybulsky; H J Fuchs; J B Baker; M A Gimbrone
Journal:  J Immunol       Date:  1991-08-01       Impact factor: 5.422

2.  IL-1 stimulates IL-6 production in endothelial cells.

Authors:  M Sironi; F Breviario; P Proserpio; A Biondi; A Vecchi; J Van Damme; E Dejana; A Mantovani
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

3.  A soluble form of the interleukin-1 receptor produced by a human B cell line.

Authors:  J A Symons; G W Duff
Journal:  FEBS Lett       Date:  1990-10-15       Impact factor: 4.124

4.  A soluble binding protein specific for interleukin 1 beta is produced by activated mononuclear cells.

Authors:  J A Symons; J A Eastgate; G W Duff
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

5.  Identification of an interleukin-1 beta binding protein in human plasma.

Authors:  J A Eastgate; J A Symons; G W Duff
Journal:  FEBS Lett       Date:  1990-01-29       Impact factor: 4.124

6.  Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor.

Authors:  J G Giri; R C Newton; R Horuk
Journal:  J Biol Chem       Date:  1990-10-15       Impact factor: 5.157

7.  Induction of an interleukin-1 receptor (IL-1R) on monocytic cells. Evidence that the receptor is not encoded by a T cell-type IL-1R mRNA.

Authors:  M K Spriggs; P J Lioubin; J Slack; S K Dower; U Jonas; D Cosman; J E Sims; J Bauer
Journal:  J Biol Chem       Date:  1990-12-25       Impact factor: 5.157

8.  Absence of inflammatory lung injury in rabbits challenged intravascularly with complement-derived chemotactic factors.

Authors:  R O Webster; G L Larsen; B C Mitchell; A J Goins; P M Henson
Journal:  Am Rev Respir Dis       Date:  1982-03

Review 9.  Interleukin-1 and interleukin-1 antagonism.

Authors:  C A Dinarello
Journal:  Blood       Date:  1991-04-15       Impact factor: 22.113

10.  Shedding of tumor necrosis factor receptors by activated human neutrophils.

Authors:  F Porteu; C Nathan
Journal:  J Exp Med       Date:  1990-08-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Membrane protein secretases.

Authors:  N M Hooper; E H Karran; A J Turner
Journal:  Biochem J       Date:  1997-01-15       Impact factor: 3.857

2.  IL-12-STAT4-IFN-gamma axis is a key downstream pathway in the development of IL-13-mediated asthma phenotypes in a Th2 type asthma model.

Authors:  You-Sun Kim; Seng-Jin Choi; Jun-Pyo Choi; Seong Gyu Jeon; Sun -Young Oh; Byung-Jae Lee; Yong Song Gho; Chun Geun Lee; Zhou Zhu; Jack A Elias; Yoon-Keun Kim
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

3.  In vivo expression of inflammatory cytokine receptors in the joint compartments of patients with arthritis.

Authors:  Tania Silvestri; Lia Pulsatelli; Paolo Dolzani; Luigi Frizziero; Andrea Facchini; Riccardo Meliconi
Journal:  Rheumatol Int       Date:  2005-03-16       Impact factor: 2.631

4.  Expression of interleukin-1beta, tumor necrosis factor alpha, and interleukin-6 in human peripheral blood leukocytes exposed to human granulocytic ehrlichiosis agent or recombinant major surface protein P44.

Authors:  H Y Kim; Y Rikihisa
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

Review 5.  Regulation of serum amyloid A protein expression during the acute-phase response.

Authors:  L E Jensen; A S Whitehead
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

6.  Constitutive repression of interleukin-1alpha in endothelial cells.

Authors:  Gregory J Brunn; Soheyla Saadi; Jeffrey L Platt
Journal:  Circ Res       Date:  2008-02-21       Impact factor: 17.367

Review 7.  Regulation of IL-1 signaling by the decoy receptor IL-1R2.

Authors:  Thomas Schlüter; Carsten Schelmbauer; Khalad Karram; Ilgiz A Mufazalov
Journal:  J Mol Med (Berl)       Date:  2018-08-15       Impact factor: 4.599

Review 8.  IL-1 receptor 2 (IL-1R2) and its role in immune regulation.

Authors:  Vanessa A Peters; Jennifer J Joesting; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2012-11-27       Impact factor: 7.217

9.  Cytokine decoy and scavenger receptors as key regulators of immunity and inflammation.

Authors:  Raffaella Bonecchi; Cecilia Garlanda; Alberto Mantovani; Federica Riva
Journal:  Cytokine       Date:  2016-08-04       Impact factor: 3.861

Review 10.  Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Authors:  Martina Molgora; Domenico Supino; Alberto Mantovani; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.